RenovoRx strengthens TAMP intellectual property as 21 cancer centers adopt RenovoCath
A new US patent allowance broadens protection around RenovoRx’s dual-occlusion drug-delivery catheter as commercial revenue grows and the separate TIGeR-PaC drug-device programme moves toward 2027 data.